Comparing Loss of Contractual Employment Pre- and Post-diagnosis in Patients with Rare Versus Common Cancer types: a National Registry-based Study

Overview

Journal J Cancer Surviv

Specialty Oncology

Date 2025 Jan 6

PMID 39760980

Authors

Amber D Zegers

Ehsan Motazedi

Eline de Heus

Vincent Ho

Pieter Coenen

Sietske J Tamminga

Saskia F A Duijts

Affiliations

Soon will be listed here.

Abstract

Purpose: Patients with rare cancer often experience diagnostic delays and limited treatment options, potentially negatively impacting their working lives. We explored whether those with rare vs. common cancer have an increased risk of loss of contractual employment (1) up to 2 years pre-diagnosis, (2) up to 5 years post-diagnosis, and (3) which characteristics of rare cancer survivors are associated with loss of contractual employment 5 years post-diagnosis.

Methods: Data from the Netherlands Cancer Registry and Statistics Netherlands were linked. Demographic, work-related, and cancer-related characteristics were obtained of 16,203 patients with rare cancer and 23,295 unmatched patients with common breast or colorectal cancer. Transitions in primary source of income were explored from contractual employment to work disability, unemployment, social welfare, (early) retirement, or self-employment. Logistic regression and competing risk survival analyses were applied.

Results: Employees with rare vs. common cancer had increased odds of becoming work-disabled pre-diagnosis (OR = 1.83, 95%CI 1.30-2.58) and of becoming self-employed post-diagnosis (HR = 1.32, 95%CI 1.03-1.68). Younger age and having a temporary employment contract were associated with becoming self-employed among those with rare cancers.

Conclusions: Employees with rare vs. common cancer have an increased risk of loss of contractual employment pre- and post-diagnosis.

Implications For Cancer Survivors: To reduce the risk of adverse work outcomes pre- and post-diagnosis, awareness and knowledge of rare cancers need to be increased to shorten time to diagnosis and accelerate access to adequate care.

References

Gatta G, van der Zwan J, Casali P, Siesling S, Dei Tos A, Kunkler I . Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011; 47(17):2493-511. DOI: 10.1016/j.ejca.2011.08.008. View

de Heus E, Duijts S, van der Zwan J, Kapiteijn E, Nieveen van Dijkum E, Van Herpen C . The gap between rare and common cancers still exists: Results from a population-based study in the Netherlands. Eur J Cancer. 2022; 167:103-111. DOI: 10.1016/j.ejca.2022.03.001. View

Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E . Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol. 2017; 18(8):1022-1039. DOI: 10.1016/S1470-2045(17)30445-X. View

Blay J, Casali P, Ray-Coquard I, Seckl M, Gietema J, de Herder W . Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN. Lancet Reg Health Eur. 2024; 39:100861. PMC: 10879812. DOI: 10.1016/j.lanepe.2024.100861. View

Butow P, Laidsaar-Powell R, Konings S, Lim C, Koczwara B . Return to work after a cancer diagnosis: a meta-review of reviews and a meta-synthesis of recent qualitative studies. J Cancer Surviv. 2019; 14(2):114-134. DOI: 10.1007/s11764-019-00828-z. View

Duijts S, Van Egmond M, Spelten E, van Muijen P, Anema J, van der Beek A . Physical and psychosocial problems in cancer survivors beyond return to work: a systematic review. Psychooncology. 2013; 23(5):481-92. DOI: 10.1002/pon.3467. View

Paltrinieri S, Fugazzaro S, Bertozzi L, Bassi M, Pellegrini M, Vicentini M . Return to work in European Cancer survivors: a systematic review. Support Care Cancer. 2018; 26(9):2983-2994. DOI: 10.1007/s00520-018-4270-6. View

de Boer A, Verbeek J, Spelten E, Uitterhoeve A, Ansink A, de Reijke T . Work ability and return-to-work in cancer patients. Br J Cancer. 2008; 98(8):1342-7. PMC: 2361697. DOI: 10.1038/sj.bjc.6604302. View

Duijts S, Dalton S, Lundh M, Horsboel T, Johansen C . Cancer survivors and return to work: current knowledge and future research. Psychooncology. 2016; 26(5):715-717. DOI: 10.1002/pon.4235. View

10.

Mehnert A . Employment and work-related issues in cancer survivors. Crit Rev Oncol Hematol. 2010; 77(2):109-30. DOI: 10.1016/j.critrevonc.2010.01.004. View

11.

Torp S, Nielsen R, Gudbergsson S, Fossa S, Dahl A . Sick leave patterns among 5-year cancer survivors: a registry-based retrospective cohort study. J Cancer Surviv. 2012; 6(3):315-23. DOI: 10.1007/s11764-012-0228-8. View

12.

de Wind A, Tamminga S, Bony C, Diether M, Ludwig M, Velthuis M . Loss of Paid Employment up to 4 Years after Colorectal Cancer Diagnosis-A Nationwide Register-Based Study with a Population-Based Reference Group. Cancers (Basel). 2021; 13(12). PMC: 8229293. DOI: 10.3390/cancers13122868. View

13.

de Boer A, Taskila T, Ojajarvi A, van Dijk F, Verbeek J . Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA. 2009; 301(7):753-62. DOI: 10.1001/jama.2009.187. View

14.

Komatsubara K, Carvajal R . The promise and challenges of rare cancer research. Lancet Oncol. 2016; 17(2):136-138. DOI: 10.1016/S1470-2045(15)00485-4. View

15.

Olischlager D, den Boer L, de Heus E, Brom L, Dona D, Klumpen H . Rare cancer and return to work: experiences and needs of patients and (health care) professionals. Disabil Rehabil. 2022; 45(16):2585-2596. DOI: 10.1080/09638288.2022.2099589. View

16.

Jain R, Menzin J, Lachance K, McBee P, Phatak H, Nghiem P . Travel burden associated with rare cancers: The example of Merkel cell carcinoma. Cancer Med. 2019; 8(5):2580-2586. PMC: 6536956. DOI: 10.1002/cam4.2085. View

17.

Buijs P, Gunnyeon B, van Weel C . Primary health care: what role for occupational health?. Br J Gen Pract. 2012; 62(605):623-4. PMC: 3505386. DOI: 10.3399/bjgp12X659141. View

18.

Huang X, Zhou G, Lv J, Zhou H, Zhong C, Wu C . Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis. Radiother Oncol. 2018; 129(2):389-395. DOI: 10.1016/j.radonc.2018.09.004. View

19.

Sjovall K, Attner B, Englund M, Lithman T, Noreen D, Gunnars B . Sickness absence among cancer patients in the pre-diagnostic and the post-diagnostic phases of five common forms of cancer. Support Care Cancer. 2011; 20(4):741-7. DOI: 10.1007/s00520-011-1142-8. View

20.

Christyani G, Carswell M, Qin S, Kim W . An Overview of Advances in Rare Cancer Diagnosis and Treatment. Int J Mol Sci. 2024; 25(2). PMC: 10815984. DOI: 10.3390/ijms25021201. View